Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.

Saved in:
Bibliographic Details
Title: Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.
Authors: Li V; Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, 3010, Australia., McKay FC; Multiple Sclerosis Australia, Suite 3.01 18 Flour Mill Way, Summer Hill, NSW, 2130, Australia. fiona.mckay@msaustralia.org.au., Tscharke DC; Immunology and Infectious Diseases, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, 2601, Australia., Smith C; Immunology Department, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia., Khanna R; Immunology Department, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia., Lechner-Scott J; University of Newcastle, School of Medicine and Public Health, Hunter Medical Research Institute, New Lambton Heights, NSW, 2305, Australia.; Department of Neurology, John Hunter Hospital, New Lambton Heights, NSW, 2305, Australia., Rawlinson WD; Serology and Virology Division (SAViD), Microbiology NSW Health Pathology, Randwick, NSW, 2031, Australia., Lloyd AR; The Kirby Institute, University of New South Wales, Kensington, NSW, 2052, Australia., Taylor BV; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 7000, Australia., Morahan JM; Multiple Sclerosis Australia, Suite 3.01 18 Flour Mill Way, Summer Hill, NSW, 2130, Australia., Steinman L; Departments of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 9305-5101, USA., Giovannoni G; Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Queen Mary University of London, London, E1 2AT, UK., Bar-Or A; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA., Levy M; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA., Drosu N; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA., Potter A; Multiple Sclerosis Australia, Suite 3.01 18 Flour Mill Way, Summer Hill, NSW, 2130, Australia., Caswell N; National Advocates, Multiple Sclerosis Australia, Summer Hill, NSW, 2130, Australia., Smith L; National Advocates, Multiple Sclerosis Australia, Summer Hill, NSW, 2130, Australia., Brady EC; National Advocates, Multiple Sclerosis Australia, Summer Hill, NSW, 2130, Australia., Frost B; National Advocates, Multiple Sclerosis Australia, Summer Hill, NSW, 2130, Australia., Hodgkinson S; School of Clinical Medicine, University of New South Wales, Liverpool, NSW, 2170, Australia., Hardy TA; Department of Neurology, Concord Hospital, University of Sydney, Concord West, NSW, 2039, Australia., Broadley SA; School of Medicine and Dentistry, Gold Coast Campus, Griffith University, Southport, QLD, 4222, Australia.; Department of Neurology, Gold Coast University Hospital, Southport, QLD, 4215, Australia.
Corporate Authors: Australian Anti-EBV Drugs for MS Working Group
Source: CNS drugs [CNS Drugs] 2025 Mar; Vol. 39 (3), pp. 305-320. Date of Electronic Publication: 2025 Jan 10.
Publication Type: Journal Article; Systematic Review
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9431220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1934 (Electronic) Linking ISSN: 11727047 NLM ISO Abbreviation: CNS Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1179-1934
DOI:10.1007/s40263-024-01153-5